

Dennis M. Erb, Ph.D.
Senior Director
Regulatory Affairs

Merck & Co., Inc.
P.O. Box 4, BLA-20
West Point PA 19486
Tel 610 397 7597
215 652 5000
Fax 610 397 2516

June 16, 1999

3504 '99 JUN 16 A9:11

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Rm. 1061
Rockville, MD 20852



**RE: Docket No. 98N-0583
FDA Proposed Rule: Export Notification
And Recordkeeping Requirements**

Merck & Co., Inc., is a leading worldwide, human health product company, and as such, Merck imports and exports products on a daily basis, and depends on the efficient flow of material to its domestic and international facilities. Thus, Merck is very much affected by regulations that impact imports and exports. For these reasons, Merck is very interested in and well qualified to comment on this FDA proposed rule on Export Notification and Recordkeeping.

Comments on Proposal

Through enactment of the FDA Export Reform and Enhancement Act of 1996 (Pub. L. No. 104-132), which amended the earlier Drug Export Amendments Act of 1986 (Pub. L. No. 99-960), Congress sought, inter alia, to ease the export of products not approved in the United States. Specifically, the Act was revised to remove restrictions that inhibited the use of US manufacturing facilities to manufacture unapproved products for offshore markets. By removing these unnecessary restrictions, Congress sought to retain jobs in the United States that might otherwise be lost to offshore manufacturing.

The regulations in the proposed rule are burdensome and contrary to both the letter and spirit of both the 1986 and 1996 drug export act amendments. Merck considers many of the reporting requirements to be a step in the wrong direction relative to the enhancements of the 1996 Export Reform Act. The proposed rule if implemented will hamper the flow of materials out of the US, reducing the ability of US companies to compete in the global market. We therefore request the FDA to consider the specific comments that follow and to reflect on the initial intent of the 1986 and 1996 drug export act amendments in revising the proposed rule.

98N-0583

C6

Specific Comments

I. Proposed 21 C.F.R. §1.101(b)(2) – Recordkeeping Requirements

FDA's proposed §1.101(b)(2) would require a letter from an appropriate government agency, department or body stating that the subject product has marketing approval from the destination country or does not conflict with that country's laws. This proposed regulation is unduly burdensome, and neither required by nor authorized by the export legislation. Obtaining such confirmatory letters from foreign officials creates a substantial administrative burden and can cause significant delay. While the export legislation permits export if the product is in accordance with the laws of the destination country, Congress did not require exporters to obtain any documentary proof from foreign officials. In many instances, the foreign government may not have provided any express marketing approval – and under such circumstances it is unrealistic to expect that the type of documentary proof proposed by the FDA may be obtained without both significant burden and delay, if at all.

Congress has nowhere asserted or implied that the advice of counsel or other corporate due diligence with respect to documenting compliance with the destination country's laws is inadequate. Yet FDA, in proposed §1.101(b)(2), has inexplicably foreclosed this very effective yet pragmatic and efficient method of ensuring compliance with the requirements of this export legislation.

§1.101(b)(2) seeks to reintroduce the very type of bureaucratic procedures that Congress intended to eliminate through the passage of this legislation. This proposed rule, if allowed to stand, will impede the export of products at best and may ultimately prevent the export of certain products.

II. Proposed 21 C.F.R. §1.101(d)(1)(iv) – Notification Requirements


FDCA §802(g) requires that, for exports to countries not listed under FDCA §802(b)(1), the exporter must provide a "simple notification" to FDA identifying both the product and the destination country. By contrast, FDCA §802(g) requires that, for exports to countries that are listed under FDCA §802(b)(1), the simple notification need identify only the exported product. Congress has been clear and unequivocal with respect to these requirements.

FDA's proposed §1.101(d)(1), however, would require that, for listed countries under FDCA §802(b)(1), the simple notification identify not only the product, but also the importing country.

This proposed rule is plainly contrary to the letter of both the 1986 and 1996 legislative amendments. FDA's claimed justification that the requirement is necessary to facilitate FDA's responsibilities is ineffectual given the clear lack of supporting statutory authority. Further, the proposed rule violates the spirit of the legislative amendments inasmuch as exporters would be required to send multiple notices as products were exported to additional listed countries. Congress' "simple notification" would become significantly complicated by the proposed rule, which is contrary to Congress' intent to ease the export of products not approved in the United States.

We trust that these comments will be considered in further development of the proposed rule. We strongly recommend that the rule be revised to bring it in line with Congress' intent in enacting the 1986 and 1996 export amendments.

Sincerely,

A handwritten signature in black ink that reads "Dennis M. Erb". The signature is written in a cursive, flowing style.


Dennis M. Erb, Ph.D.
Senior Director
Regulatory Affairs

FedEx USA AirbillFedEx
Tracking
Number

810495663520

Form
I.O. No.

0210

SPH32
Recipient's Copy**1 From**
Date 6/15/99Sender's Name Dennis M. Erb, Ph.D Phone 610 397-7597Company MERCK SHARP & DOHMEAddress 5 SENTRY PKWY WEST East BLA-20 Dept./Floor/Suite/RoomCity BLUE BELL State PA ZIP 19422**2** Your Internal Billing Reference Information**3 To**
Recipient's Name Docketz Mgmt. Branch Phone ()Company Food and Drug Administration HFA-305Address 5630 Fishers Lane Room 1061 Dept./Floor/Suite/Room
(To "HOLD" at FedEx location, print FedEx address here)City Rockville State MD ZIP 20852**For HOLD at FedEx Location check here**☐ **Hold Weekday**
(Not available with
FedEx First Overnight)☐ **Hold Saturday**
(Available for FedEx Priority Overnight
and FedEx 2Day only)**For WEEKEND Delivery check here** (Extra Charge. Not available at all locations)☐ **Saturday Delivery**
(Available for FedEx Priority
Overnight and FedEx 2Day only)☐ **NEW Sunday Delivery**
(Available for FedEx
Priority Overnight only)

8 1 0 4 9 5 6 6 3 5 2 0

4a Express Package Service Packages under 150 lbs. Delivery commitment may be later in some areas.
☒ **FedEx Priority Overnight** (Next business morning)
☐ **FedEx Standard Overnight** (Next business afternoon)
☐ **FedEx First Overnight** (Earliest next business morning delivery to select locations) (Higher rates apply)
☐ **FedEx 2Day** (Second business day)
☐ **FedEx Express Saver** (Third business day)
FedEx Letter Rate not available. Minimum charge: One pound rate.**4b Express Freight Service Packages over 150 lbs.** Delivery commitment may be later in some areas.
☐ **FedEx Overnight Freight** (Next business day)
☐ **FedEx 2Day Freight** (Second business day)
☐ **FedEx Express Saver Freight** (Up to 3 business days)
(Call for delivery schedule. See back for detailed descriptions of freight services.)**5 Packaging** ☒ **FedEx Letter** ☐ **FedEx Pak** ☐ **FedEx Box** ☐ **FedEx Tube** ☐ **Other Pkg.**
Declared value limit \$500.**6 Special Handling** (One box must be checked)
Does this shipment contain dangerous goods? ☐ No ☐ Yes (Shipper's Declaration) ☐ Yes (Shipper's Declaration not required)
☐ **Dry Ice** ☐ **Cargo Aircraft Only**
Dry Ice, S, UN 1845 x kg
*Dangerous Goods cannot be shipped in FedEx packaging.**7 Payment** ☐ **Obtain Recipient FedEx Account No.**
Bill to: ☒ **Sender** (Account No. in Section 1 will be billed) ☐ **Recipient** (Enter FedEx Account No. or Credit Card No. below) ☐ **Third Party** ☐ **Credit Card** ☐ **Cash/Check**

| Total Packages | Total Weight | Total Declared Value* | Total Charges |
|----------------|--------------|-----------------------|---------------|
| | | \$.00 | \$ |

*When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information.

Credit Card Auth.

8 Release Signature

Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

Questions?
Call 1-800-Go-FedEx® (800)463-3339

0085547061

321

WCSL 1296
Rev. Data 7/98
Part #150023os
©1994-98 FedEx
PRINTED IN U.S.A.